Key Dates

Related Announcements

RFA-DA-22-004 - Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This Notice informs applicants of a change to the Key Dates for Funding Opportunity Announcement (FOA) RFA-DA-22-004, "Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)".  Please Note: This RFA will only accept AIDS applications.  

 
The following section of RFA-DA-22-004, "Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)" has been modified, as indicated below, to reflect new dates.

Currently Reads:

Part 1. Overview Information
 
Key Dates

Open Date (Earliest Submission Date):

June 14, 2021

Letter of Intent Due Date(s):

July 7, 2021

Expiration Date:

July 15, 2022

Modified to Read (changes shown in bold italics):

Part 1. Overview Information

Key Dates

Open Date (Earliest Submission Date):

July 10, 2021

Letter of Intent Due Date(s):

30 days prior to application due date.  

Expiration Date:

August 11, 2022

All other aspects of this FOA remain the same.  

Inquiries

Please direct all inquiries to:

Shang-Yi Anne Tsai, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5842
Email: [email protected]